Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Multidimensionale Phänotypisierung für eine personalisierte präventive Ernährungsunterstützung für ältere Menschen (MetabotypAGE)

Neue partizipative Forschungsstrategie und multidimensionale Phänotypisierung für personalisierte präventive Ernährungsunterstützung für ältere Menschen

There is high inter-individual variability in the response to feeding, which is determined by multiple interacting factors such as age, sex, genotype, gut microbiota, eating behaviors, physical activity or even socio-demographic factors. Original studies have recently demonstrated the possibility of predicting the postprandial response to the diet of healthy individuals on the basis of in-depth phenotyping, and of offering them foods adapted to their own metabolic capacities according to their belonging to different groups of individuals defined on the basis of the similarity of their metabolic capacities. Due to different life trajectories, inter-individual variability could be amplified upon entry into the aging period, which could explain at least in part why traditional strategies for managing chronic age-related pathologies are insufficient. The investigators aim is to propose a new strategy to better understand inter-individual variability in the response to food in the elderly based on deep phenotyping.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

During a first phase of the project, the investigators defined all the parameters that could be measured to realize a deep phenotyping of volunteers to establish "metabotypes" and have a better understanding of the variability in the response to food. These parameters include: kinetics of change in postprandial blood glucose over a period of 4 hours following home consumption of four types of test meals (composite nutritional test); and measurement of several blood parameters either in the post-absorptive state, or in the post-prandial state, either after test meals at home, or after a fat meal in the research facility: triglycerides, insulin, C-Reactive-Protein, metabolites through open metabolomics, albumin, fatty acids, cytokines, different gene expression. Through questionnaires or tests the investigators will also assess:

food habits and preferences (with a special focus on polyphenols), olfactory and taste abilities, physical activity, muscle functionality, body composition, peripheral endothelial function and microvascular stiffness, blood pressure, oral status, cognitive function, stress and depression status, intestinal function, psycho-socio-economic status. Finally, the investigators will constitute a collection of blood, white cell, plasma, serum, saliva, urine and stool samples.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

180

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Clermont-Ferrand, Frankreich, 63009
        • Plateforme d'Exploration de la Mobilité (CHU Clermont-Ferrand)
      • Clermont-Ferrand, Frankreich, 63100
        • Centre de Recherche en Odontologie Clinique, Faculté de Chirurgie Dentaire
    • France
      • Clermont-Ferrand, France, Frankreich, 63000
        • Pic / Cic-Inserm 1405

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

60 Jahre bis 75 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • - Subject with grip strength (assessed with a dynamometer) ≥16kg for women and ≥26 kg for men.
  • 21 ≤ BMI ≤35
  • Participant living in a rural or peri-urban area or city dweller, according to the population density grid of the Territorial Observatory (categories 3, 2 or 1 respectively).
  • Cognitively able to perform tests and answer questionnaires according to the judgment of the recruiting doctor and on the basis of the Mini-Mental State Examination (MMSE)
  • Available to carry out the entire protocol
  • Biological assessment considered by the investigator as compatible with participation in the study,
  • Subject agreeing to give written consent, and registration in the national file of volunteers who lend themselves to research
  • Person subject to a social security system.

Exclusion Criteria:

  • - Diabetes treated
  • Sub-acute pathology (flu, gastroenteritis, bacterial infection, etc.) or trauma (fracture, surgical intervention, etc.) in the 30 days preceding inclusion.
  • Hepatocellular insufficiency,
  • Heart failure with decompensation,
  • Renal insufficiency (clearance <30 ml/min)
  • Chronic anti-inflammatory treatment, long-term corticosteroid therapy > 1 month, infiltrations
  • Antibiotic treatment within 30 days prior to recruitment
  • Progressive pathology at the time of inclusion (cancer, etc.)
  • Gastrointestinal pathology deemed incompatible with the protocol
  • Eating habits incompatible with the protocol (allergies, test food intolerances/aversions, vegan diets, ketogenic diets, etc.)
  • Unstabilized thyroid diseases
  • Intense physical activity (activity causing shortness of breath and sweating) > 10 hours per week
  • Person who is in a period of exclusion on the National File of Healthy Volunteers
  • Subject presenting a psychiatric pathology or cognitive disorders making them incapable of giving informed consent.
  • Subject under guardianship, curatorship, deprived of freedoms or under the protection of justice

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Verhütung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Non dependant 60 to 75 year-old men and women

Deep phenotyping, including metabolic response to nutritional tests.

Metabolic responses to several test meals

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Characterize the inter-individual variability of the blood glucose postprandial response
Zeitfenster: Within the first month of study realization

Kinetics of change in postprandial blood glucose over a period of 4 hours following home consumption of four types of test meals by continuously monitoring blood glucose

Within the first month of study realization

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Questionnaires about food habits and preferences (with a special focus on polyphenols)
Zeitfenster: Within the three months of study realization

The investigators' objective is to have a good understanding of eating habits: estimation of precise food intake over three days but also long-term eating habits, preferences for sweet foods, salty foods, fatty foods. Participants will also be questioned about their general appetite, their neophobia, their culinary habits. An effort will be made to estimate polyphenol intake through specific questions.

Within the three months of study realization
Test to assess taste abilities
Zeitfenster: Within the first week of study realization

The participants will be offered drinks containing either water (n=2) or salted water (n=8), with various concentrations of salt. The objective is to determine which drinks contain salt or not. The score will vary from 0 (only bad answers) to 8 (only good answers). A score of 8 thus means that the taste abilities are good.

Within the first week of study realization
Test to assess olfactory abilities
Zeitfenster: Within the first week of study realization

Six groups of 4 vials will be presented to the participants. For each group of 4, only one vial has an odor. The first step will be to find the vial that does contain an odor. Then, the participant will have to identify the odor, choosing among 4 proposed odor. The score will increase with the number of vial found and the number of correct odor identification. It will thus vary from 0 to 8. If a participant has a score of 8, it means that he could detect each time in which vial there was an odor, and could each time identify the odor. Thus a score of 8 denotes very good olfactory abilities.

Within the first week of study realization
Time to walk 4 meters
Zeitfenster: Within the first two months of study realization

The time to walk 4 m will be measured.

Within the first two months of study realization
Time to stand up 5 times from a chair
Zeitfenster: Within the first two months of study realization

The time to stand up 5 times from a chair will be measured.

Within the first two months of study realization
Maximum tolerated muscle power
Zeitfenster: Within the first two months of study realization

The maximum tolerated muscle power will be measured on a cycloergometer

Within the first two months of study realization
Maximal isometric strength
Zeitfenster: Within the first two months of study realization

The maximal isometric strength of the quadriceps will be measured on an isometric measuring bench.

Within the first two months of study realization
Questionnaires about usual physical activity
Zeitfenster: Within the first two months of study realization

The objective is to assess the amount of time usually spent by the participant for physical activity and for sedentary activities, the intensity of activities, through 28 questions. This questionnaire will give a categorical score, with 3 levels of physical activity: 1) Low: no physical activity or only low intensity activities. 2) Moderate: 3 or more days of intense activity lasting at least 20 min per day, or 5 days or more of moderate intensity activity and/or walking for at least 30 minutes per day, or 5 days or more of activity combining walking, moderate or high intensity activities. 3) Intense activity at least 3 days per week or 7 days or more of activity combining walking, moderate or high intensity activities

Within the first two months of study realization
Measurement of total body lean mass (kg)
Zeitfenster: Within the first two months of study realization

Lean body mass will be measured by multi frequency electrical bio impedance (Bodystat QuadScan 4000). A weak electric current is delivered to the subject through electrodes, and the voltage is measured in order to calculate impedance (resistance and reactance) of the body. Most body water is stored in muscle. Therefore, if a person is more muscular there is a high chance that the person will also have more body water, which leads to lower impedance. Using the weight of the participant, through calibration curves, the system then calculates total body water, total body fat mass, and total body lean mass.

Within the first two months of study realization
Measurement of total body fat mass (kg)
Zeitfenster: Within the first two months of study realization

Fat body mass will be measured by multi frequency electrical bio impedance (Bodystat QuadScan 4000). A weak electric current is delivered to the subject through electrodes, and the voltage is measured in order to calculate impedance (resistance and reactance) of the body. Most body water is stored in muscle. Therefore, if a person is more muscular there is a high chance that the person will also have more body water, which leads to lower impedance. Using the weight of the participant, through calibration curves, the system then calculates total body water, total body fat mass, and total body lean mass.

Within the first two months of study realization
Measurement of peripheral endothelial function (RHI, %)
Zeitfenster: Within the first week of study realization

Peripheral endothelial function of the participants will be assessed by tonometry using the Endo-PAT X system (Itamar Medical Ltd) before and after induction of post-occlusive reactive hyperemia. Endothelium-induced changes in vascular tone are measured at the fingertip using a pair of single-use plethysmographic sensors. The result obtained is the Reactive Hyperemia Index (RHI, %) which corresponds to the ratio between the amplitudes of the PAT® (Peripheral Arterial Tonometry) signal during hyperemia and the basal amplitudes of the occluded side, normalized by the values of the control arm. The values will be considered as normal if inferior to 1.67, and abnormal if higher than 1.67.

Within the first week of study realization
Measurement of microvascular stiffness (Augmentation Index)
Zeitfenster: Within the first week of study realization

Microvascular stiffness (=Augmentation Index) of the participants will be assessed by tonometry using the Endo-PAT X system (Itamar Medical Ltd). Augmentation Index (AI) will be calculated from the shape of the pulse wave recorded in basal conditions. This measurement is a recognized marker of cardiovascular risk. The AI value is inversely proportional to the stiffness of the vessels. The scale of the measurement is the following:

Values between 20-80: healthy degree of arterial flexibility. Values between 81-100 : increased cardiovascular risk Values over 100: high cardiovascular risk.

Within the first week of study realization
Assessment of oral status
Zeitfenster: Within the first two months of study realization.

Oral status will be assessed through the Nordic Orofacial Test - Screening (NOT-S), which is a screening and evaluation tool for orofacial motor dysfunctions and disorders. It includes two parts: 1) "Maintenance" part containing 6 sections: sensory function, breathing, habits, chewing and swallowing, drooling, and dry mouth (I-VI); 2) "Examination" part comprising 6 sections: face at rest, nasal breathing, facial expression, function of the masticatory muscles and jaws, oral motor functions, and articulation of speech. The NOT-S total score ranges from 0 (no dysfunction) to 12 (high dysfunction). For each section, from the moment the subject answers "Yes" to one of the questions, the box is checked and results in a score of 1 in the last right column of the questionnaire.

Within the first two months of study realization.
Assessment of cognitive function
Zeitfenster: Within the first week of study realization

The cognitive abilities of the participants will be assessed using the CANTAB®, using a computer under supervision. This method makes it possible to assess 1) episodic memory; 2) verbal recognition memory, that is, immediate and delayed memory for verbal information; 3) Spatial working memory, which requires the retention and manipulation of visuospatial information. 4) The spatial span task (CANTAB spatial spam), which evaluates the maximum amount of information that the subject is capable of recalling after a single presentation.

Within the first week of study realization
Assessment of depression status
Zeitfenster: Within the first week of study realization.

Participants' depressive nature will be assessed using the Geriatric Depression Scale (GDS) test. It is a self-questionnaire which contains 15 items, each with a binary Yes-No response. It is a commonly used tool to assess the presence of depressive symptoms in older adults. A score of 0 to 5 is considered normal. A score between 5 and 9 indicates a high likelihood of depression, and a score between 10 and 15 almost always indicates depression.

Within the first week of study realization.
Assessment of socio-economic status
Zeitfenster: Within the three months of study realization

The socio-economic status of participants will be assessed using the EPICES scale (Évaluation de la Précarité et des Inégalités de santé dans les Centres d'Examens de Santé) which was developed in France by the National Institute of Prevention and Education for Health . This scale is used in public health to assess the social precariousness of individuals, which takes into account the multidimensional nature of precariousness. The main interest of the EPICES score consists of understanding populations which, while escaping the traditional administrative indicators of precariousness, present the same health risks. The EPICES score is based on 11 questions which summarize 90% of a subject's precarious situation. The answer to each question is assigned a coefficient, the sum of the 11 answers gives the EPICES score. The score is continuous, it varies from 0 (absence of precariousness) to 100 (maximum of precariousness).

Within the three months of study realization
Assessment of self-esteem
Zeitfenster: Within the three months of study realization

Participants' self-esteem will be assessed using the Rosenberg Self-Esteem Scale. It is a psychometric tool widely used in psychology research, social sciences and clinical settings. It consists of 10 questions to which respondents are asked to indicate their degree of agreement or disagreement using a 4-point Likert scale, ranging from "strongly disagree" to "strongly agree". The questions are designed to assess overall self-perception and personal esteem. The score between 10 and 40 which are interpreted according to specific thresholds.Higher scores indicate higher self-esteem.

Within the three months of study realization
Assessment of intestinal function
Zeitfenster: Within the first month of study realization

To have a better understanding of the characteristics of the participants' intestinal function, they will have to complete an intestinal transit diary. Such a diary is a tool used to record a person's stool habits and characteristics over a period of time. It is often used in the field of gastroenterology and nutrition to assess the functioning of the digestive system. Participants will note every day for 15 days: the frequency of stools, noting each time the time they had a bowel movement, as well as the consistency of stools based on the Bristol visual scale. which categorizes 7 types of stools, ranging from the hardest to the softest. Experts consider types 1 and 2 to be uncharacteristically hard and indicative of constipation, while types 6 and 7 are unusually loose and may indicate diarrhea. Medical professionals generally consider types 3, 4, and 5 to be the most typical. Overall, a qualitative assessment of intestinal function will be made, with no calculated score.

Within the first month of study realization
Stool collection
Zeitfenster: Within the first month of study realization

One sample of stool will be taken and analyzed by metagenomic.

Within the first month of study realization
Measurement of plasma insulin levels (micro U / mL)
Zeitfenster: Within the first two months of study realization

These measurements will be made 1) in the post-absorptive state, 2) after the ingestion of 4 standards test meals, 3) after the ingestion of a sweet and fatty meal.

Within the first two months of study realization
Measurement of plasma triglycerides levels (mg / dL)
Zeitfenster: Within the first two months of study realization

These measurements will be made 1) in the post-absorptive state, 2) after the ingestion of 4 standards test meals, 3) after the ingestion of a sweet and fatty meal.

Within the first two months of study realization
Measurement of plasma C Reactive Protein (mg / L)
Zeitfenster: Within the first two months of study realization

These measurements will be made in the post-absorptive state.

Within the first two months of study realization
Measurement of plasma amino acid levels (µMol)
Zeitfenster: Within the first two months of study realization

These measurements will be made 1) in the post-absorptive state 2) after the ingestion of a protein rich test meal.

Within the first two months of study realization
Measurement of plasma metabolite through open metabolomics
Zeitfenster: Within the first two months of study realization

These measurements will be made 1) in the post-absorptive state 2) after the ingestion of a sweet and fatty meal.

Within the first two months of study realization
Measurement of plasma free fatty acids (mg / L)
Zeitfenster: Within the first two months of study realization

These measurements will be made 1) in the post-absorptive state 2) after the ingestion of a sweet and fatty meal.

Within the first two months of study realization
Measurement of plasma cytokines (U / L)
Zeitfenster: Within the first two months of study realization

These measurements will be made 1) in the post-absorptive state 2) after the ingestion of a sweet and fatty meal.

Within the first two months of study realization
Measurement of plasma albumin (g / L)
Zeitfenster: Within the first two months of study realization

These measurements will be made in the post-absorptive state

Within the first two months of study realization
Measurement of various gene expression in peripheral blood mononuclear cells isolated from blood samples.
Zeitfenster: Within the first two months of study realization

These measurements will be made in the post-absorptive state

Within the first two months of study realization
Measurement of plasma oxylipins (nmol / L)
Zeitfenster: Within the first two months of study realization.

These measurements will be made 1) in the post-absorptive state 2) after the ingestion of a sweet and fatty meal.

Within the first two months of study realization.
Measurement of immune responsiveness (whole blood oxylipin and cytokine responses to immune stimulation).
Zeitfenster: Within the first two months of study realization.

These measurements will be made in the post-absorptive state.

Within the first two months of study realization.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Gisèle Pichering, Pr, Centre d'Investigation Clinique

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

14. Februar 2024

Primärer Abschluss (Tatsächlich)

30. Oktober 2026

Studienabschluss (Tatsächlich)

30. Oktober 2026

Studienanmeldedaten

Zuerst eingereicht

10. November 2023

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

1. Dezember 2023

Zuerst gepostet (Tatsächlich)

11. Dezember 2023

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

6. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

3. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • INRAE-UNH-2023-1

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

Sharing of all IPD that underlie results in a publication

IPD-Sharing-Zeitrahmen

Beginning 6 months after publication, and for as long as necessary after that

IPD-Sharing-Zugriffskriterien

The data will be shared with any researcher who requests it by email following publication.

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .